한글목차

유방암 액체생검 시장의 규모는 최근 급속히 확대하고 있습니다. 2025년 8억 9,000만 달러에서 2026년에는 10억 2,000만 달러로, CAGR 14.6%로 성장이 전망되고 있습니다. 지난 수년간의 성장 요인으로는 유방암 발병률 상승, 조직 생검의 한계, 종양 진단 기술의 발전, 검진 인식 증가, 검사실 확충 등을 꼽을 수 있습니다.

유방암 액체생검 시장 규모는 향후 수년간 급성장이 전망됩니다. 2030년에는 14.3%의 CAGR로 17억 5,000만 달러에 달할 전망입니다. 예측 기간의 성장은 정밀 종양학 도입, AI 기반 돌연변이 분석, 개인 맞춤형 치료 계획, cfDNA 검사 확대, 분산형 암 진단 등에 기인할 것으로 보입니다. 예측 기간의 주요 동향으로는 다중 바이오마커 혈액검사, 비침습적 암 모니터링, 치료 반응 추적, 조기 재발 감지, 개인 맞춤형 종양 진단 등을 들 수 있습니다.

유방암 환자 수 증가는 향후 수년간 유방암 액체생검 시장의 성장을 촉진할 것으로 예측됩니다. 유방암은 유방 세포, 특히 유즙을 생산하는 소엽과 유즙을 유두로 운반하는 유관에 발생하는 악성 종양입니다. 유방암 발병률 증가는 유전적 소인, 호르몬 불균형, 노화, 생활습관 변화, 비만, 음주, 운동부족, 방사선 노출, 환경오염물질 등의 요인에 기인하는 것으로 알려져 있습니다. 유방암 액체생검은 혈액내 순환 종양 DNA(ctDNA) 또는 순환 종양 세포(CTCs)를 검출하여 질병의 실시간 모니터링을 가능하게 함으로써 치료에 중요한 역할을 합니다. 치료 효과 평가, 치료 저항성 검출, 표적 치료를 위한 유전자 돌연변이 확인에 도움이 됩니다. 예를 들어 암 조사, 교육, 홍보, 환자 지원 활동을 하는 미국 비영리단체인 미국암협회에 따르면 2024년 31만 3,510건에서 2025년 31만 9,750건으로 유방암 신규 발병 건수가 증가할 것으로 예측했습니다. 그 결과, 유방암 발생률 증가는 유방암 액체생검 시장의 확대를 촉진하고 있습니다.

유방암 액체생검 시장의 주요 기업은 특정 치료법의 혜택을 가장 많이 받을 가능성이 가장 높은 환자를 식별하고 개인 맞춤형 치료를 촉진하기 위해 동반 진단과 같은 혁신적 개발에 집중하고 있습니다. 동반진단제는 액체생검 기술을 활용하여 치료 반응성을 나타내는 유전자 변이, 순환종양 DNA(ctDNA), 단백질 발현 등의 바이오마커를 검출합니다. 예를 들어 2023년 1월 미국 생명공학 기업 가디언트 헬스(Guardant Health)는 진행성 또는 전이성 유방암 환자 중 ESR1 돌연변이가 있는 환자를 위한 치료제인 메나리니 그룹(Menarini Group)의 오르셀듀(Erasestrant)의 동반 진단으로 자사의 가디언트 360 CDx 액체생검 검사가 미국 식품의약국(FDA)의 승인을 받았습니다. 이번 승인으로 종양 전문의들은 이 검사를 통해 종합적인 유전체 프로파일링을 실시하여 표적 치료의 혜택을 받을 수 있는 환자를 선별할 수 있게 되었습니다. 또한 가드앤트헬스의 유방암 분야 최초의 FDA 승인으로 정밀 종양학 분야에서 가드앤트헬스의 입지를 강화하는 계기가 될 것으로 보입니다.

목차

제1장 개요

제2장 시장의 특징

제3장 시장 공급망 분석

제4장 세계 시장 동향과 전략

제5장 최종 용도 산업의 시장 분석

제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의에 의한 공급망에 대한 영향, Covid가 시장에 미치는 영향을 포함한 거시경제 시나리오

제7장 세계의 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석

제8장 시장의 세계 TAM(Total Addressable Market)

제9장 시장 세분화

제10장 지역별·국가별 분석

제11장 아시아태평양 시장

제12장 중국 시장

제13장 인도 시장

제14장 일본 시장

제15장 호주 시장

제16장 인도네시아 시장

제17장 한국 시장

제18장 대만 시장

제19장 동남아시아 시장

제20장 서유럽 시장

제21장 영국 시장

제22장 독일 시장

제23장 프랑스 시장

제24장 이탈리아 시장

제25장 스페인 시장

제26장 동유럽 시장

제27장 러시아 시장

제28장 북미 시장

제29장 미국 시장

제30장 캐나다 시장

제31장 남미 시장

제32장 브라질 시장

제33장 중동 시장

제34장 아프리카 시장

제35장 시장 규제 상황과 투자환경

제36장 경쟁 구도와 기업 개요

제37장 기타 대기업과 혁신적 기업

제38장 세계의 시장 경쟁 벤치마킹과 대시보드

제39장 주요 합병과 인수

제40장 시장의 잠재력이 높은 국가, 부문, 전략

제41장 부록

영문목차

A breast cancer liquid biopsy is a minimally invasive test that detects and analyzes tumor-derived materials in a patient's blood or other bodily fluids, offering valuable insights into the presence, progression, and genetic profile of breast cancer without the need for a traditional tissue biopsy.

The primary products used in breast cancer liquid biopsy include consumables and kits. Consumables refer to disposable materials, reagents, and kits utilized in liquid biopsy tests to detect and analyze biomarkers associated with breast cancer. The key biomarkers include extracellular vesicles (EVs), cell-free DNA (cfDNA), circulating tumor RNA (ctRNA), circulating tumor cells (CTCs), cell-free RNA (cfRNA), and others. These biomarkers are applied in early detection or screening, diagnosis, and other purposes. The end users of breast cancer liquid biopsy encompass laboratories, hospitals, physician laboratories, reference laboratories, public health laboratories, research institutes, small molecular laboratories, and pathology laboratories.

Tariffs have created cost pressures in the breast cancer liquid biopsy market by impacting the supply of sequencing reagents, PCR consumables, and diagnostic kits. Consumables and kits segments are most affected, particularly in North America and Europe due to dependence on Asia-Pacific manufacturing hubs. While tariffs have increased testing costs, they have also encouraged local kit manufacturing, reagent optimization, and development of cost-efficient multi-marker solutions.

The breast cancer liquid biopsy market research report is one of a series of new reports from The Business Research Company that provides breast cancer liquid biopsy market statistics, including breast cancer liquid biopsy industry global market size, regional shares, competitors with a breast cancer liquid biopsy market share, detailed breast cancer liquid biopsy market segments, market trends and opportunities, and any further data you may need to thrive in the breast cancer liquid biopsy industry. This breast cancer liquid biopsy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The breast cancer liquid biopsy market size has grown rapidly in recent years. It will grow from $0.89 billion in 2025 to $1.02 billion in 2026 at a compound annual growth rate (CAGR) of 14.6%. The growth in the historic period can be attributed to rising breast cancer prevalence, limitations of tissue biopsy, oncology diagnostic advancements, increased screening awareness, laboratory testing expansion.

The breast cancer liquid biopsy market size is expected to see rapid growth in the next few years. It will grow to $1.75 billion in 2030 at a compound annual growth rate (CAGR) of 14.3%. The growth in the forecast period can be attributed to precision oncology adoption, AI-based mutation analysis, personalized treatment planning, growth in cfDNA testing, decentralized cancer diagnostics. Major trends in the forecast period include multi-biomarker blood-based testing, non-invasive cancer monitoring, treatment response tracking, early recurrence detection, personalized oncology diagnostics.

The rising number of breast cancer cases is expected to drive the growth of the breast cancer liquid biopsy market in the coming years. Breast cancer is a malignancy that originates in the breast cells, typically in the milk-producing lobules or the ducts that transport milk to the nipple. The increasing prevalence of breast cancer is attributed to factors such as genetic predisposition, hormonal imbalances, an aging population, lifestyle changes, obesity, alcohol consumption, physical inactivity, radiation exposure, and environmental pollutants. Breast cancer liquid biopsy plays a crucial role in treatment by detecting circulating tumor DNA (ctDNA) or circulating tumor cells (CTCs) in the blood, enabling real-time disease monitoring. It helps assess treatment response, detect therapy resistance, and identify genetic mutations for targeted therapies. For example, according to the American Cancer Society, a US-based nonprofit organization dedicated to cancer research, education, advocacy, and patient support, new breast cancer cases are projected to increase from 313,510 in 2024 to 319,750 in 2025. As a result, the growing incidence of breast cancer is fueling the expansion of the breast cancer liquid biopsy market.

Leading companies in the breast cancer liquid biopsy market are focusing on innovative developments, such as companion diagnostics, to facilitate personalized treatment by identifying patients who are most likely to benefit from specific therapies. Companion diagnostics leverage liquid biopsy technology to detect biomarkers, including genetic mutations, circulating tumor DNA (ctDNA), and protein expressions that indicate treatment responsiveness. For instance, in January 2023, Guardant Health Inc., a US-based biotechnology company, received Food and Drug Administration (FDA) approval for its Guardant360 CDx liquid biopsy test as a companion diagnostic for Menarini Group's ORSERDU (elacestrant), a therapy for advanced or metastatic breast cancer patients with ESR1 mutations. This approval allows oncologists to conduct comprehensive genomic profiling using the test, enabling them to identify patients who may benefit from targeted therapy. It also marks Guardant Health's first FDA approval for breast cancer, strengthening its presence in precision oncology.

In January 2024, Guardant Health Inc. partnered with Hikma Pharmaceuticals plc to enhance early cancer detection, monitor recurrence, and optimize treatment selection using Guardant Health's advanced liquid and tissue biopsy technologies. This collaboration strengthens Guardant Health's global presence and addresses the increasing cancer burden in the Middle East and North Africa. Hikma Pharmaceuticals plc is a UK-based pharmaceutical company specializing in innovative healthcare solutions.

Major companies operating in the breast cancer liquid biopsy market are Johnson & Johnson Private Limited, Roche Diagnostics, Merck KGaA, Thermo Fisher Scientific, Siemens Healthineers, Agilent Technologies Inc., Illumina Inc., Sysmex Corporation, Qiagen N.V., Myriad Genetics Inc., NeoGenomics Laboratories, Guardant Health Inc., Twist Bioscience, Foundation Medicine Inc., Biodesix Inc., Menarini Silicon Biosystems, Datar Cancer Genetics, Abcam plc, OncoDNA SA, Genomic Health Inc., RainDance Technologies, Biocept Inc., Fluxion Biosciences Inc., Angle plc

North America was the largest region in the breast cancer liquid biopsy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the breast cancer liquid biopsy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the breast cancer liquid biopsy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The breast cancer liquid biopsy market consists of revenues earned by entities by providing services such as early cancer detection, treatment monitoring, minimal residual disease (MRD) detection, recurrence prediction, and genetic mutation analysis for targeted therapy selection. The market value includes the value of related goods sold by the service provider or included within the service offering. The breast cancer liquid biopsy market also includes sales of circulating tumor DNA (ctDNA) assay kits, circulating tumor cell (CTC) detection systems, next-generation sequencing (NGS) panels, PCR-based liquid biopsy tests, blood collection tubes, and consumables and reagents used for non-invasive cancer diagnostics and monitoring. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Breast Cancer Liquid Biopsy Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses breast cancer liquid biopsy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for breast cancer liquid biopsy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The breast cancer liquid biopsy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Product: Consumables; Kits
• 2) By Biomarkers: Extracellular Vesicles (EVs); Cell-free DNA (cfDNA); Circulating Tumor RNA (ctRNA); Circulating Tumor Cells (CTCs); Cell-free RNA (cfRNA); Other Biomarkers
• 3) By Application: Early Detection Or Screening; Diagnosis; Other Applications
• 4) By End Users: Laboratories; Hospitals; Physician Laboratories; Reference Laboratories; Public Health Laboratories; Research Institutes; Small Molecular Laboratories; Pathology Laboratories
• Subsegments:
• 1) By Consumables: Reagents; Polymerase Chain Reaction (PCR) Assays; Sequencing Panels; Sample Collection Tubes
• 2) By Kits: DNA-based Liquid Biopsy Kits; RNA-based Liquid Biopsy Kits; Multi-marker Liquid Biopsy Kits
• Companies Mentioned: Johnson & Johnson Private Limited; Roche Diagnostics; Merck KGaA; Thermo Fisher Scientific; Siemens Healthineers; Agilent Technologies Inc.; Illumina Inc.; Sysmex Corporation; Qiagen N.V.; Myriad Genetics Inc.; NeoGenomics Laboratories; Guardant Health Inc.; Twist Bioscience; Foundation Medicine Inc.; Biodesix Inc.; Menarini Silicon Biosystems; Datar Cancer Genetics; Abcam plc; OncoDNA SA; Genomic Health Inc.; RainDance Technologies; Biocept Inc.; Fluxion Biosciences Inc.; Angle plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Breast Cancer Liquid Biopsy Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Breast Cancer Liquid Biopsy Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Breast Cancer Liquid Biopsy Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Breast Cancer Liquid Biopsy Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Artificial Intelligence & Autonomous Intelligence
  • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.4 Industry 4.0 & Intelligent Manufacturing
  • 4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
• 4.2. Major Trends
  • 4.2.1 Multi-Biomarker Blood-Based Testing
  • 4.2.2 Non-Invasive Cancer Monitoring
  • 4.2.3 Treatment Response Tracking
  • 4.2.4 Early Recurrence Detection
  • 4.2.5 Personalized Oncology Diagnostics

5. Breast Cancer Liquid Biopsy Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Diagnostic Laboratories
• 5.3 Physician Laboratories
• 5.4 Research Institutes
• 5.5 Pathology Laboratories

6. Breast Cancer Liquid Biopsy Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Breast Cancer Liquid Biopsy Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Breast Cancer Liquid Biopsy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Breast Cancer Liquid Biopsy Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Breast Cancer Liquid Biopsy Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Breast Cancer Liquid Biopsy Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Breast Cancer Liquid Biopsy Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Breast Cancer Liquid Biopsy Market Segmentation

• 9.1. Global Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Consumables, Kits
• 9.2. Global Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Extracellular Vesicles (EVs), Cell-free DNA (cfDNA), Circulating Tumor RNA (ctRNA), Circulating Tumor Cells (CTCs), Cell-free RNA (cfRNA), Other Biomarkers
• 9.3. Global Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Early Detection Or Screening, Diagnosis, Other Applications
• 9.4. Global Breast Cancer Liquid Biopsy Market, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Laboratories, Hospitals, Physician Laboratories, Reference Laboratories, Public Health Laboratories, Research Institutes, Small Molecular Laboratories, Pathology Laboratories
• 9.5. Global Breast Cancer Liquid Biopsy Market, Sub-Segmentation Of Consumables, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Reagents, Polymerase Chain Reaction (PCR) Assays, Sequencing Panels, Sample Collection Tubes
• 9.6. Global Breast Cancer Liquid Biopsy Market, Sub-Segmentation Of Kits, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• DNA-based Liquid Biopsy Kits, RNA-based Liquid Biopsy Kits, Multi-marker Liquid Biopsy Kits

10. Breast Cancer Liquid Biopsy Market Regional And Country Analysis

• 10.1. Global Breast Cancer Liquid Biopsy Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Breast Cancer Liquid Biopsy Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Breast Cancer Liquid Biopsy Market

• 11.1. Asia-Pacific Breast Cancer Liquid Biopsy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Breast Cancer Liquid Biopsy Market, Segmentation By Product, Segmentation By Biomarkers, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Breast Cancer Liquid Biopsy Market

• 12.1. China Breast Cancer Liquid Biopsy Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Breast Cancer Liquid Biopsy Market, Segmentation By Product, Segmentation By Biomarkers, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Breast Cancer Liquid Biopsy Market

• 13.1. India Breast Cancer Liquid Biopsy Market, Segmentation By Product, Segmentation By Biomarkers, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Breast Cancer Liquid Biopsy Market

• 14.1. Japan Breast Cancer Liquid Biopsy Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Breast Cancer Liquid Biopsy Market, Segmentation By Product, Segmentation By Biomarkers, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Breast Cancer Liquid Biopsy Market

• 15.1. Australia Breast Cancer Liquid Biopsy Market, Segmentation By Product, Segmentation By Biomarkers, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Breast Cancer Liquid Biopsy Market

• 16.1. Indonesia Breast Cancer Liquid Biopsy Market, Segmentation By Product, Segmentation By Biomarkers, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Breast Cancer Liquid Biopsy Market

• 17.1. South Korea Breast Cancer Liquid Biopsy Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Breast Cancer Liquid Biopsy Market, Segmentation By Product, Segmentation By Biomarkers, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Breast Cancer Liquid Biopsy Market

• 18.1. Taiwan Breast Cancer Liquid Biopsy Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Breast Cancer Liquid Biopsy Market, Segmentation By Product, Segmentation By Biomarkers, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Breast Cancer Liquid Biopsy Market

• 19.1. South East Asia Breast Cancer Liquid Biopsy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Breast Cancer Liquid Biopsy Market, Segmentation By Product, Segmentation By Biomarkers, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Breast Cancer Liquid Biopsy Market

• 20.1. Western Europe Breast Cancer Liquid Biopsy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Breast Cancer Liquid Biopsy Market, Segmentation By Product, Segmentation By Biomarkers, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Breast Cancer Liquid Biopsy Market

• 21.1. UK Breast Cancer Liquid Biopsy Market, Segmentation By Product, Segmentation By Biomarkers, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Breast Cancer Liquid Biopsy Market

• 22.1. Germany Breast Cancer Liquid Biopsy Market, Segmentation By Product, Segmentation By Biomarkers, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Breast Cancer Liquid Biopsy Market

• 23.1. France Breast Cancer Liquid Biopsy Market, Segmentation By Product, Segmentation By Biomarkers, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Breast Cancer Liquid Biopsy Market

• 24.1. Italy Breast Cancer Liquid Biopsy Market, Segmentation By Product, Segmentation By Biomarkers, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Breast Cancer Liquid Biopsy Market

• 25.1. Spain Breast Cancer Liquid Biopsy Market, Segmentation By Product, Segmentation By Biomarkers, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Breast Cancer Liquid Biopsy Market

• 26.1. Eastern Europe Breast Cancer Liquid Biopsy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Breast Cancer Liquid Biopsy Market, Segmentation By Product, Segmentation By Biomarkers, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Breast Cancer Liquid Biopsy Market

• 27.1. Russia Breast Cancer Liquid Biopsy Market, Segmentation By Product, Segmentation By Biomarkers, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Breast Cancer Liquid Biopsy Market

• 28.1. North America Breast Cancer Liquid Biopsy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Breast Cancer Liquid Biopsy Market, Segmentation By Product, Segmentation By Biomarkers, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Breast Cancer Liquid Biopsy Market

• 29.1. USA Breast Cancer Liquid Biopsy Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Breast Cancer Liquid Biopsy Market, Segmentation By Product, Segmentation By Biomarkers, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Breast Cancer Liquid Biopsy Market

• 30.1. Canada Breast Cancer Liquid Biopsy Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Breast Cancer Liquid Biopsy Market, Segmentation By Product, Segmentation By Biomarkers, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Breast Cancer Liquid Biopsy Market

• 31.1. South America Breast Cancer Liquid Biopsy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Breast Cancer Liquid Biopsy Market, Segmentation By Product, Segmentation By Biomarkers, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Breast Cancer Liquid Biopsy Market

• 32.1. Brazil Breast Cancer Liquid Biopsy Market, Segmentation By Product, Segmentation By Biomarkers, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Breast Cancer Liquid Biopsy Market

• 33.1. Middle East Breast Cancer Liquid Biopsy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Breast Cancer Liquid Biopsy Market, Segmentation By Product, Segmentation By Biomarkers, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Breast Cancer Liquid Biopsy Market

• 34.1. Africa Breast Cancer Liquid Biopsy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Breast Cancer Liquid Biopsy Market, Segmentation By Product, Segmentation By Biomarkers, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Breast Cancer Liquid Biopsy Market Regulatory and Investment Landscape

36. Breast Cancer Liquid Biopsy Market Competitive Landscape And Company Profiles

• 36.1. Breast Cancer Liquid Biopsy Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Breast Cancer Liquid Biopsy Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Breast Cancer Liquid Biopsy Market Company Profiles
  • 36.3.1. Johnson & Johnson Private Limited Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Roche Diagnostics Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Merck KGaA Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Thermo Fisher Scientific Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Siemens Healthineers Overview, Products and Services, Strategy and Financial Analysis

37. Breast Cancer Liquid Biopsy Market Other Major And Innovative Companies

• Agilent Technologies Inc., Illumina Inc., Sysmex Corporation, Qiagen N.V., Myriad Genetics Inc., NeoGenomics Laboratories, Guardant Health Inc., Twist Bioscience, Foundation Medicine Inc., Biodesix Inc., Menarini Silicon Biosystems, Datar Cancer Genetics, Abcam plc, OncoDNA SA, Genomic Health Inc.

38. Global Breast Cancer Liquid Biopsy Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Breast Cancer Liquid Biopsy Market

40. Breast Cancer Liquid Biopsy Market High Potential Countries, Segments and Strategies

• 40.1 Breast Cancer Liquid Biopsy Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Breast Cancer Liquid Biopsy Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Breast Cancer Liquid Biopsy Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer